Overexpression of Indoleamine 2,3-Dioxygenase 1 Promotes Epithelial-Mesenchymal Transition by Activation of the IL-6/STAT3/PD-L1 Pathway in Bladder Cancer-Reference-Cited by-同舟云学术

Overexpression of Indoleamine 2,3-Dioxygenase 1 Promotes Epithelial-Mesenchymal Transition by Activation of the IL-6/STAT3/PD-L1 Pathway in Bladder Cancer

Published:2019-03 Issue:3 Volume:12 Page:485-492
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Zhang Wentao,Zhang Junfeng,Zhang Ziwei,Guo Yadong,Wu Yuan,Wang Ruiliang,Wang Longsheng,Mao Shiyu,Yao Xudong

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. Cancer statistics, 2016;Siegel;CA Cancer J Clin,2016

2. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer;Alfred Witjes;Eur Urol,2017

3. The metabolism of tryptophan. 2. The metabolism of tryptophan in patients suffering from cancer of the bladder;Boyland;Biochem J,1956

4. Epithelial-mesenchymal transition in human prostate cancer demonstrates enhanced immune evasion marked by IDO1 expression;Kolijn;Cancer Res,2018

5. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment;Schafer;Oncotarget,2016

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery, synthesis and biological evaluation of novel isoquinoline derivatives as potent indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase dual inhibitors;European Journal of Medicinal Chemistry;2024-12

2. Immune-checkpoint gene expression and BCG response in non-muscle invasive bladder cancer;Translational Oncology;2024-08

3. A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302);BMC Cancer;2024-07-25

4. Breaking Barriers: Modulation of Tumor Microenvironment to Enhance Bacillus Calmette–Guérin Immunotherapy of Bladder Cancer;Cells;2024-04-18

5. Integrating the PD-L1 Prognostic Biomarker in Non-Muscle Invasive Bladder Cancer in Clinical Practice—A Comprehensive Review on State-of-the-Art Advances and Critical Issues;Journal of Clinical Medicine;2024-04-10